Skip to Content Skip to Search

Our pipeline

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.

 

Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.

 

The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.

 

For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

 

Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

 

This quarterly pipeline information was updated on 28 April 2021.

 

NOTE: For Oncology, only the most advanced indication (tumor type or line of therapy) in clinical development is shown.

For COVID-19 vaccines, GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations.

Download full pipeline in XLSX

XLSX - 24.2KB

Key

†
In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations

NOTE: For Oncology, only the most advanced indication (tumor type or line of therapy) in clinical development is shown.

Pipeline last updated 28 April 2021.

  • Additional indication
  • Immuno-modulator

Key

†
In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations

NOTE: For Oncology, only the most advanced indication (tumor type or line of therapy) in clinical development is shown.

Pipeline changes from Q4 2020 to Q1 2021.

Key

†
In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations

NOTE: For Oncology, only the most advanced indication (tumor type or line of therapy) in clinical development is shown.

  • Additional indication
  • Immuno-modulator

No results - Please try with another term

Quick Links

Find out more